Incorporation of DMNoMore Ltd in England and Wales

Investment window for SEIS and EIS fundraise opens

Investment window for SEIS and EIS fundraise closes

Preclinical study completed

DMNoMore deck with results sent to Investors

Investment window for Early seed fundraise opens

Early seed closes

Rebrand to reflect platform approach of AIM therapy

Seed Window opens

Seed Window closes

T1D therapeutic asset manufacture commenced

T1D therapeutic asset manufacture validation commenced

T1D therapeutic asset manufacture and validation optimization complete

CRO and CMC partners engaged in cGMP production

Named as Department for International Trade LifeSciences Innovator 2023

JP Morgan Biotech Showcase presenter 2023

Innovate UK Edge grant awarded